Aptevo Therapeutics Inc. (APVO)
Automate Your Wheel Strategy on APVO
With Tiblio's Option Bot, you can configure your own wheel strategy including APVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol APVO
- Rev/Share 0.0
- Book/Share -1.01
- PB -4.7328
- Debt/Equity -3.002
- CurrentRatio 0.6688
- ROIC -8.1719
- MktCap 3346000.0
- FreeCF/Share -16.2562
- PFCF -0.1411
- PE -0.2941
- Debt/Assets 0.5301
- DivYield 0
- ROE -7.7942
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share ("Common Stock"), at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on May 23, 2025, at 5:01 p.m.
Read More
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical studies, APVO711 demonstrates dual anti-cancer functionality with broad solid tumor potential and developability SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today provided a program update for APVO711, a dual mechanism bispecific utilizing the PD-L1 arm to block the PD-1/PD-L1 pathway and the CD40 arm to enhance T cell priming …
Read More
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
SEATTLE, WA / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced today that it has entered into definitive securities purchase agreements for the purchase and sale of 2,324,000 shares of the Company's common stock in a registered direct offering (the "offering") at a purchase price of $0.862 per share. The offering is expected to close on or about April 22, 2025 subject to the satisfaction of customary closing conditions.
Read More
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced today that it has entered into definitive securities purchase agreements for the purchase and sale of 1,764,710 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 3,529,420 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1.19 per share and …
Read More
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform doublet combination benchmark No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date Cohort 2 enrollment nears completion SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced two additional frontline AML patients have achieved remission* within 30 days of treatment in the …
Read More
About Aptevo Therapeutics Inc. (APVO)
- IPO Date 2016-07-20
- Website https://www.aptevotherapeutics.com
- Industry Biotechnology
- CEO Mr. Marvin L. White
- Employees 37